NA
TGTX icon

NewEdge Advisors’s TG Therapeutics TGTX Stock Holding History

NewEdge Advisors’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$555K Buy
10,103
+1,343
+15% +$55K ﹤0.01% 2077
2026
Q1 		$291K Buy
8,760
+53
+0.6% +$1.58K ﹤0.01% 2357
2025
Q4 		$260K Buy
8,707
+20
+0.2% +$653 ﹤0.01% 2412
2025
Q3 		$314K Buy
8,687
+1,094
+14% +$36K ﹤0.01% 2142
2025
Q2 		$273K Hold
7,593
– – ﹤0.01% 2072
2025
Q1 		$299K Buy
7,593
+665
+10% +$22.4K ﹤0.01% 1899
2024
Q4 		$209K Buy
6,928
+6,779
+4,550% +$195K ﹤0.01% 2073
2024
Q3 		$3.48K Buy
+149
New +$3.25K ﹤0.01% 3270
2023
Q3 		– Sell
-9,359
Closed -$232K – 3651
2023
Q2 		$232K Buy
9,359
+8,959
+2,240% +$231K ﹤0.01% 1574
2023
Q1 		$6.02K Buy
+400
New +$6.08K ﹤0.01% 2720

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

NewEdge Advisors's TGTX Position: Q2 2026 in Review

NewEdge Advisors increased its TG Therapeutics (TGTX) stake by 15% in Q2 2026, buying an estimated $55K and bringing the position to 10,103 shares worth $555K. The position accounts for ﹤0.01% of the portfolio, ranked #2077.

NewEdge Advisors first reported a position in TGTX in Q1 2023 and has held it in 10 quarters since. 429 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • NewEdge Advisors held 10,103 shares of TG Therapeutics worth $555K as of Q2 2026.
  • NewEdge Advisors bought 1,343 TG Therapeutics shares in Q2 2026, an estimated $55K.
  • TG Therapeutics made up ﹤0.01% of NewEdge Advisors's portfolio in Q2 2026, its #2077 holding.
  • NewEdge Advisors first reported a position in TG Therapeutics in Q1 2023 and has held it in 10 quarters since.
  • 429 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on NewEdge Advisors's 13F filing for Q2 2026, filed 12 Aug 2026.